Research brief · 2026-09-09
What 'Half-Life' Means and Why It Matters for Peptides
Half-life is one of those terms that gets thrown around in peptide discussions as if everyone agrees what it means. The definition is simple: it is the time it takes for the concentration of a substance in the blood to fall by half. After one half-life, half remains. After two, a quarter. After about five, a substance is essentially gone, a rule of thumb found in any standard pharmacology text such as Rowland and Tozer's Clinical Pharmacokinetics.
The reason it matters so much for peptides is biology. Peptides are short chains of amino acids, and the body treats them like food. Enzymes in the blood, gut and kidneys cut peptide bonds quickly. A 2018 review by Lau and Dunn in Bioorganic and Medicinal Chemistry lists this rapid breakdown, along with poor oral absorption, as the defining challenges that peptide drug design has spent decades working around.
The cleanest example is GLP-1. Drucker's 2018 review in Cell Metabolism reports that the natural hormone survives only about two minutes in circulation before the enzyme DPP-4 disables it. That is fine for a signal your gut sends after a meal, but useless as a medicine. Semaglutide, a prescription medication approved by the FDA for type 2 diabetes and chronic weight management, was engineered with two changes: a substitution that blocks DPP-4, and a fatty-acid chain that lets it ride on the blood protein albumin. Its FDA prescribing information lists a half-life of about one week. Same receptor, very different clock.
What half-life does not tell you is how strongly something acts, or for how long its effects persist after clearance. It also varies between individuals with kidney function, body composition and age. Half-life is a clearance number, not a benefit number, and any question about what it means for a specific medication belongs with a physician or pharmacist.
Sources
- Lau JL, Dunn MK, Therapeutic peptides: Historical perspectives, current development trends, and future directions
- Bioorganic & Medicinal Chemistry 2018
- Drucker DJ, Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- Cell Metabolism 2018
- Ozempic (semaglutide) prescribing information, U.S. Food and Drug Administration
- FDA label 2017, revised 2025
- Rowland M, Tozer TN, Clinical Pharmacokinetics and Pharmacodynamics, 4th ed.
- Lippincott Williams & Wilkins 2011
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.